A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: A pilot study

Leukemia and Lymphoma

Volumn 47, Issue 10, 2006, Pages 2147-2154

  Rech, Juergen ^a   Repp, Roland ^b   Rech, Dorit ^a   Stockmeyer, Bernhard ^a   Dechant, Michael ^c   Niedobitek, Gerald ^a   Gramatzki, Martin ^b   Valerius, Thomas ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Antibody therapy; G CSF; HLA class II; Non Hodgkin's lymphoma; Remitogen

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; APOLIZUMAB; EPITOPE; HLA DR ANTIGEN; MONOCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FOLLICULAR LYMPHOMA; GENETIC POLYMORPHISM; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MALE; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; SKIN MANIFESTATION; THROMBOCYTOPENIA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HLA-DR ANTIGENS; HUMANS; LEUKOCYTES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 33750477308     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600757944     Document Type: Article

References (26)

1. Scholl, P and Geha, R. (1994) MHC class II signaling in B-cell activation Immunol Today, 15, pp. 418-422.
2. Dechant, M and Bruenke, J and Valerius, T. (2003) HLA class II antibodies for the therapy of hematologic malignancies Semin Oncol, 30, pp. 465-475.
3. deNardo, G and O'Donnell, R and Rose, L and Mirick, G and Kroger, L and DeNardo, S. (1999) Milestones in the development of Lym-1 therapy Hybridoma, 18, pp. 1-11.
4. Gingrich, R and Dahle, C and Hoskins, K and Senneff, M. (1990) Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes Blood, 75, pp. 2375-2387.
5. Kostelny, S and Link, B and Tso, J and Vasquez, M and Jorgensen, B and Wang, H and (2001) Humanization and characterization of the anti-HLA-DR antibody 1D10 Int J Cancer, 93, pp. 556-565.
6. Shi, J and Bullock, C and Hall, W and Wescott, V and Wang, H and Levitt, D and (2002) In vivo pharmacodynamic effects of Hu1D10 (Remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells Leuk Lymphoma, 43, pp. 1303-1312.
7. Link, B and Kahl, B and Czuczman, M and Powell, B and Bartlett, N and Leonard, J and (2001) A phase II study of Remitogen (Hu1D10), a humanized monoclonal antibody, in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma Blood, 98, pp. 606a.
8. Link, B and Wang, H and Byrd, J and Leonhard, J and Davis, T and Flinn, I and (2001) Phase I study of Hu1D10 monoclonal antibody (Remitogen) in patients with B-cell lymphoma Proc Am Soc Clin Oncol, pp. 1135. abstract
9. Link, B and Wang, H and Byrd, J and Leonhard, J and Davis, T and Flinn, I and (2001) Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-HLA-DR monoclonal antibody Remitogen (Hu1D10) Blood, 98, pp. 244b.
10. Elsässer, D and Valerius, T and Repp, R and Weiner, G and Deo, Y and Kalden, J and (1996) HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with G-CSF Blood, 87, pp. 3803-3812.
11. Würflein, D and Dechant, M and Stockmeyer, B and Tutt, A and Hu, P and Repp, R and (1998) Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B-cells Cancer Res, 58, pp. 3051-3058.
12. Di Carlo, E and Forini, G and Lollini, P and Colombo, M and Modesti, A and Musiani, P. (2001) The intriguing role of polymorphonuclear neutrophils in antitumor reactions Blood, 97, pp. 339-345.
13. Repp, R and Valerius, T and Sendler, A and Gramatzki, M and Iro, H and Kalden, J and (1991) Neutrophils express the high affinity receptor for IgG (FcγRI; CD64) after in vivo application of rhG-CSF Blood, 78, pp. 885-889.
14. Valerius, T and Repp, R and de Wit, T and Berthold, S and Platzer, E and Kalden, J and (1993) Involvement of the high affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy Blood, 82, pp. 931-939.
15. Hernandez-Ilizaliturri, F and Jupudy, V and Ostberg, J and Oflazoglu, E and Huberman, A and Repasky, E and (2003) Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model Clin Cancer Res, 9, pp. 5866-5873.
16. Hernandez-Ilizaliturri, F and Jupudy, V and Reising, S and Repasky, E and Czuczman, M. (2005) Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model Leuk Lymphoma, 46, pp. 1775-1784.
17. Vaickus, L and Biddle, W and Cemerlic, D and Foon, K. (1990) Interferon-γ augments Lym-1-dependent, granulocyte-mediated tumor cell lysis Blood, 75, pp. 2408-2416.
18. Ottonello, L and Epstein, A and Dapino, P and Barbera, P and Morone, P and Dallegri, F. (1999) Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony- stimulating factor: Intervention of FcγRII (CD32), CD11b-CD18 intergrins, and CD66b glycoproteins Blood, 93, pp. 3505-3511.
19. van der Kolk, L and Grillo-Lopez, A and Baars, J and van Oers, M. (2003) Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: Final report on safety and efficacy Leukemia, 17, pp. 1658-1664.
20. Stockmeyer, B and Schiller, M and Repp, R and Lorenz, H and Kalden, J and Gramatzki, M and (2002) Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor (G-CSF)-primed effector cells and Hu1D10 - a humanized HLA DR antibody Br J Haematol, 118, pp. 959-967.
21. Lin, T and Stock, W and Lucas, M and Porcu, P and (2002) A phase I dose escalation study of apolizumab (Hu1D10) using a stepped up dosing schedule in patients with chronic lymphocytic leukemia and acute lymphocytic leukemia Blood, 100, pp. 802a.
22. Nagy, Z and Hubner, B and Löhning, C and Rauchenberger, R and Reiffert, S and Thomassen-Wolf, E and (2002) Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells Nat Med, 8, pp. 801-807.
23. van der Kolk, L and Grillo-Lopez, A and Baars, J and Hack, C and van Oers, M. (2001) Complement activation plays a key role in the side-effects of rituximab treatment Br J Haematol, 115, pp. 807-811.
24. Diehl, L and Ketchum, L. (1998) Autoimmune disease and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia Semin Oncol, 25, pp. 80-97.
25. Robak, T and Blasinska-Morawiec, M and Krykowski, E and Hellmann, A and Konopka, L. (1997) Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukemia treated with 2-chlorodeoxyadenosine (cladribine) Eur J Haematol, 58, pp. 109-113.
26. Dechant, M and Vidarsson, G and Stockmeyer, B and Repp, R and Glennie, M and Gramatzki, M and (2002) Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing Blood, 100, pp. 4574-4580.